Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. (Q36648790)

15 August 2017

Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. (English)

1 reference

15 August 2017

B J Allen

1

1 reference

15 August 2017

Z Tian

2

1 reference

15 August 2017

S M A Rizvi

3

1 reference

15 August 2017

Y Li

4

1 reference

15 August 2017

M Ranson

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

88

1 reference

15 August 2017

6

1 reference

15 August 2017

944-950

1 reference

In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Biological and clinical aspects of plasminogen activator inhibitor type 2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Antibodies in diagnosis and therapy. The magic bullet--nearing the century mark

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Directed plasminogen activation at the surface of normal and malignant cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Tumor-associated urokinase-type plasminogen activator: biological and clinical significance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

The urokinase-type plasminogen activator system in cancer metastasis: A review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Antitumor activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377077

Radioimmunotherapy with alpha-emitting nuclides

20 September 2018

1 reference

12 December 2020

Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry

1 reference

12 December 2020

In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers

1 reference

12 December 2020

Can alpha-immunotherapy succeed where other systemic modalities have failed?

1 reference

12 December 2020

Targeted alpha particle immunotherapy for myeloid leukemia

1 reference

12 December 2020

An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation

1 reference

12 December 2020

Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells

1 reference

12 December 2020

Preclinical targeted alpha therapy for subcutaneous melanoma

1 reference

12 December 2020

211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y

1 reference

12 December 2020

Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules

1 reference

12 December 2020

Radioimmunoconjugates for targeted alpha therapy of malignant melanoma

1 reference

12 December 2020

Optimizations of Radiolabeling of Immunoproteins with 213Bi

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600838

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6600838

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

12644835

1 reference